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The promise of epigenome-wide association studies and cancer-specific somatic DNA methylation changes in improving our
understanding of cancer, coupled with the decreasing cost and increasing coverage of DNA methylation microarrays, has brought
about a surge in the use of these technologies. Here, we aim to provide both a review of issues encountered in the processing and
analysis of array-based DNA methylation data and a summary of the advantages of recent approaches proposed for handling
those issues, focusing on approaches publicly available in open-source environments such as R and Bioconductor. We hope that
the processing tools and analysis flowchart described herein will facilitate researchers to effectively use these powerful DNA
methylation array-based platforms, thereby advancing our understanding of human health and disease.
Epigenetic mechanisms associated with DNA methylation of
cytosine residues at CpG dinucleotides have a central role in
normal human development and disease (Baylin and Jones, 2011).
Advancements in high-throughput assessment of DNA methyla-
tion using microarrays or second-generation sequencing-based
approaches have enabled the quantitative profiling of DNA
methylation of CpG loci throughout the genome. As well as
profiling the methylome of tumour compared with normal tissue,
this has ushered in the era of epigenome-wide association studies,
analogous to the genome-wide association studies, aimed at
understanding the epigenetic basis of complex diseases such as
cancer. The promise of methylation profiling in improving our
understanding of cancer coupled with the current trend of
decreasing cost and increasing coverage of DNA methylation
microarrays has brought about a surge in the use of these
technologies.
Here, we aim to provide both a review of issues encountered in
the processing and analysis of array-based DNA methylation data
and a summary of recent approaches proposed for handling those
issues. Excellent reviews in the field of epigenetics and technical
aspects of array-based assessment of DNA methylation are
available, although this is a constantly developing research area
(Laird, 2010; Petronis, 2010; Baylin and Jones, 2011; Rakyan et al,
2011; Bock, 2012). We seek to update perspectives on statistical
issues that arise in the processing and analysis of array-based DNA
methylation data (Siegmund, 2011), highlighting more recent
methods proposed for this purpose. The subheadings shown in
Figure 1 form the basis for the topics highlighted in this review.
Our aim is to help researchers understand the growing body of
statistical methods for array-based DNA methylation data,
focusing on those freely available in open-source environments
such as R or Bioconductor (Table 1). For this review, we chose to
focus on Illumina’s BeadArray assays; however, many of the
general considerations described here are applicable to other array
technologies. We also aim to counter some of the perceived
limitations of these arrays, that is, there are too many ‘false
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positives’ in analysing microarray data (Ioannidis, 2007). We
present the viewpoint that appropriate experimental design and
downstream data processing and analysis pipelines will enable
DNA methylation to be appropriately analysed and will help in
understanding the pathogenesis of human disease.
ILLUMINA BEADARRAY TECHNOLOGY FOR
METHYLATION
Illumina adapted its BeadArray technology for genotyping to
recognise bisulphite-converted DNA for the interrogation of DNA
methylation (Bibikova et al, 2011). The Illumina BeadArray assays
use oligonucleotides conjugated to bead types to measure specific
target sequences, measuring multiple beads per bead type. The
bead types are summarised by the average signal for methylated
(M) and unmethylated (U) alleles, and are used to compute the
b-value, where
b ¼ MaxðM; 0Þ
MaxðM; 0ÞþMaxðU; 0Þþ100
A b-value of 0 equates to an unmethylated CpG site and 1 to a
fully methylated CpG site. Illumina has developed three platforms
for array-based assessment of DNA methylation: GoldenGate,
Infinium Human Methylation27 and the Infinium HD 450K
methylation array, which all use two fluorescent dye colours but
differ in the chemistries used to recognise the bisulphite-converted
sequence; however, we will focus on the Infinium arrays for the rest
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Figure 1. Methylation array data processing and analysis pipeline.
Table 1. R/Bioconductor packages for the processing and analysis of array-based DNA methylation data
DNA methylation processing/analysis step R/Bioconductor packages
Quality control samples IMA, HumMethQCReport, methylkit, MethyLumi, preprocessing and analysis pipeline, minfi
Quality control probes IMA, HumMethQCReport, lumi, LumiWCluster, preprocessing and analysis pipeline, wateRmelon
Background correction Limma, lumi, MethyLumi, minfi, preprocessing and analysis pipeline
Normalisation Combata, HumMethQCReport, lumi, minfi, TurboNorm, MethyLumi, wateRmelon
Type 1 and 2 probe scaling IMA, minfi, wateRmelon
Batch/plate/chip/confounder adjustment Combata, CpGassoc, ISVA, MethLAB
Data dimension reduction MethyLumi
Differential methylation analysis/region-based analysis CpGAssoc, IMA, limma, methylkit, MethLAB, MethVisual, minfi, EVORA
Clustering/profile analysis Lumi, ISVA, HumMeth27QCReport, methylkit, RPMM, SS-RPMMb
Multiple testing correction CpGAssoc, methylkit, MethLAB, NHMMfdr
aFreely available for download: http://www.bu.edu/jlab/wp-assets/ComBat/Abstract.html.
bFreely available for download: http://bio-epi.hitchcock.org/faculty/koestler.html.
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of this work, as the GoldenGate array has been phased out from
production. Furthermore, Illumina has developed their Genome-
Studio software (Bibikova et al, 2011), which enables basic data
analysis; however, for more in-depth analysis, many tools have
been developed, as we will discuss below.
QUALITY CONTROL OF SAMPLES
The Infinium arrays include several control probes for determining
the data quality, including sample-independent and -dependent
controls (Illumina, 2011). To detect poorly performing samples in
Illumina arrays, diagnostic plots of control probes in Genome-
Studio are often used (Bibikova et al, 2011), and the R-package
HumMethQCReport (Mancuso et al, 2011) also provides these
plots. Figure 2 shows hybridisation and bisulphite conversion plots
for 450K data in the green channel. Although the sample-
independent and -dependent controls can be visually inspected
to identify poor performing samples, an alternative approach
involves using the raw signal intensities of the control probes and
determining whether they are beyond the expected range
(e.g., median±3 s.d.) of the signal intensities across all samples.
Other options for quality control of samples, which make use of
detection P-values, are available in R and Bioconductor packages,
such as the preprocessing and analysis pipeline (Touleimat and
Tost, 2012), IMA (Wang et al, 2012), Minfi (Hansen and Aryee,
2013) and MethyLumi (Davis et al, 2011).
QUALITY CONTROL OF PROBES
Similar to sample quality control, it is customary to filter probes if
a certain proportion of samples (i.e., 425%) have a detection
P-value below a certain prespecified threshold (i.e., Po0.05)
(Bibikova et al, 2011). In the IMA package (Wang et al, 2012),
probes with missing values, those residing on the X chromosome,
and those with a median detection P-value 40.05 across samples
can be filtered out; other packages allowing such filtering include
(Davis et al, 2011; Touleimat and Tost, 2012).
LumiWCluster (Kuan et al, 2010) includes a function for model-
based clustering of methylation data using a weighted likelihood
approach wherein higher-quality samples (i.e., those with a low
median detection P-value) have larger weights and thus greater
influence on the estimation of the mixture parameters for cluster
inference. This approach avoids discarding probes, characteristic of
hard-thresholding approaches, allowing the incorporation of all the
data while accounting for the quality of individual observations.
A potential issue for quality control at the probe level stems
from certain probes targeting CpG loci, which include single-
nucleotide polymorphisms (SNPs) near or within the probe
sequence or even in the target CpG dinucleotide; in fact, there
may be up to 25% probes on the 450K array that are affected by an
SNP (Liu et al, 2013). As methylation levels of a specific locus
may be influenced by genotype (Dedeurwaerder et al, 2011a),
investigators may want to remove those SNP-associated loci from
their data, and several R packages have options for carrying this
out (Touleimat and Tost, 2012; Wang et al, 2012). Genetic effects,
however, should not be underestimated in methylation arrays. As
was recently demonstrated in Fraser et al (2012), a large portion of
population-specific DNA methylation levels may in fact be due to
population-specific genetic variants, which are themselves affected
by genetic or environmental interactions. Although rare SNPs are
unlikely to affect methylation levels to a large extent, somatic
mutations can impact methylation levels greatly, such as driver
mutations in a tumour; hence, the importance of subsequent
sequencing validation.
Additional probes that a researcher may want to remove from
their data include the ‘Chen probes’. This is evidenced in a recently
published paper showing that there may be spurious cross-
hybridisation of Infinium probes on the 450K array and further
suggesting that cross-hybridisation to the sex chromosomes may
account for the large gender effects that researchers have found on
the autosomal chromosomes (Chen et al, 2013). Finally, a number
of SNP probes are also included on the Infinium array that can
help identify mislabelled samples, as implemented in wateRmelon
(Pidsley et al, 2013).
BACKGROUND CORRECTION
Background correction is platform specific, helps to remove
nonspecific signal from total signal and corrects for between-array
artefacts. Although this can be performed using Illumina’s
GenomeStudio, several R packages contain background correction
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Figure 2. Quality control example from GenomeStudio 450K data.
(A) Hybridisation quality control plot in the green channel. (B) Bisulphite
conversion quality control plot in the green channel. In this example,
the separation between high and low values indicates that hybridisation
worked well. Furthermore, bisulphite conversion also performed well as
converted controls have a higher signal than unconverted controls.
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functions. This includes the preprocessing and analysis pipeline for
450K data (Touleimat and Tost, 2012), providing background-level
correction using lumi (Du, 2008), and furthermore Limma
(Wettenhall and Smyth, 2004) and MethyLumi (Davis et al,
2011). Background can also be estimated by direct estimation from
the density modes of the intensities measured by each probe.
However, the latter has been shown to produce aberrant DNA
methylation profiles, so using negative control probes may be
preferred (Touleimat and Tost, 2012). One can also use Minfi
(Hansen and Aryee, 2013) as a background estimation method;
however, the authors acknowledge that this method may result in
differing values compared with those estimated via GenomeStudio.
NORMALISATION
Normalisation concerns the removal of sources of experimental
artefacts, random noise and technical and systematic variation
caused by microarray technology, which, if left unaddressed, has
the potential to mask true biological differences (Sun et al, 2011a).
Two different types of normalisation exist: (1) between-array
normalisation, removing technical artefacts between samples on
different arrays, and (2) within-array normalisation, correcting for
intensity-related dye biases (Siegmund, 2011).
Owing to the features of DNA methylation, there is a lack of
consensus regarding the optimal approach for normalisation of
methylation data. Specifically, there is an imbalance in methylation
levels throughout the genome creating a skewness to the
methylation log-ratio distribution; the degree of this skewness is
dependent on the levels of methylation in particular samples
(Siegmund, 2011). This imbalance is due to the non-random
distribution of CpG sites throughout the genome and the link
between CpG density and DNA methylation; for instance, CpG
islands (CGI) are often unmethylated, whereas the opposite
relationship is typically seen in non-CGIs in normal human cells
(Baylin and Jones, 2011). Furthermore, total fluorescence signal is
inversely related to DNA methylation levels (Siegmund, 2011).
Many available normalisation methods were designed for gene
expression array data and are based on assumptions that may not
be appropriate for DNA methylation microarray data.
GenomeStudio provides an internal control normalisation
method for the 450K assay (Illumina, 2008), which is also used
in MethyLumi (Davis et al, 2011) and Minfi (Hansen and Aryee,
2013); by default, Genomestudio uses the first sample in the array
as the reference and allows the user to reselect the reference sample
as needed if the original sample is nongenomic or of poor quality.
Quantile normalisation is one of the most commonly used
normalisation techniques. Locally weighted scatterplot smoothing
(LOESS) normalisation is an intensity-dependent normalisation
method that assumes independence between the difference in log
fluorescence signals between two samples and the average of the
log signals from the two dyes (Siegmund, 2011). Quantile and
LOESS normalisation (Laird, 2010) assume similar total signal
across samples and can therefore remove true biological signal,
because of the nature of DNA methylation described above, and
have assumptions unlikely to hold for methylation data. As the
Infinium I and II probe types examine different subsets of the
genome, described in detail below, quantile normalisation cannot
be applied indiscriminantly across probe types.
Lumi (Du, 2008), also used in HumMethQCReport (Mancuso
et al, 2011), offers an alternative to quantile normalisation through
a robust spline normalisation, which is designed to normalise
variance-stabilised data by combining features of both quantile and
LOESS normalisation (Du, 2008). Another approach, subset
quantile normalisation (Wu and Aryee, 2010), normalises the data
on the basis of on a subset of negative control or CpG-free probes
that are independent of DNA methylation but suffers the same
issues as other quantile approaches. The TurboNorm R package
(van Iterson et al, 2012) provides an alternative to LOESS
normalisation using a weighted P-spline intensity-dependent
normalisation technique and can be applied to two colour arrays.
A more recent method (Johnson et al, 2007), which we describe in
more detail below, performs both normalisation and batch-effect
correction. A comparison of different normalisation pipelines for
Illumina 450K data can be found in two recent publications
(Marabita et al, 2013; Pidsley et al, 2013).
TYPE I AND II PROBE SCALING
Another potential methodological concern stems from the fact that
the 450K array uses two different types of probes, prompting the
recommendation of rescaling to make the probe distributions
comparable (Bibikova et al, 2011). Specifically, the 450K array has
485 577 probes, of which 72% use the Infinium type II primer
extension assay where the unmethylated (red channel) and
methylated (green channel) signals are measured by a single bead
(Bibikova et al, 2011). The remainder use the Infinium type I
primer extension assay (also used in the 27K Infinium array) where
the unmethylated and methylated signals are measured by different
beads in the same colour channel (Bibikova et al, 2011).
Importantly, the two probes differ in terms of CpG density, with
more CpGs mapping to CpG islands for type I probes (57%) as
compared with type II probes (21%) (Bibikova et al, 2011).
Moreover, compared with Infinium I probes, the range of b-values
obtained from the Infinium II probes is smaller; in addition, the
Infinium II probes also appear to be less sensitive for the detection
of extreme methylation values and display a greater variance
between replicates (Dedeurwaerder et al, 2011a).
The divergence in the methylation distribution range has
implications for statistical analysis of the array data. For example,
in a supervised analysis of all probes, an enrichment bias towards
type I probes may be created when ranking probes because of the
higher range of type I probes (Maksimovic et al, 2012). In addition,
region-based analyses assume that probes within those regions are
comparable, potentially untenable because of the diverging
chemistries on the 450K array (Maksimovic et al, 2012). Moreover,
when performing profile analyses or clustering, the differing
chemistries between the two probes types may drive the clustering
solution.
Attempts have been made to use rescaling to ‘repair’ the
divergence between these two types of probes. The first correction
method proposed was peak-based correction (Dedeurwaerder et al,
2011a), implemented in IMA (Wang et al, 2012), wherein the
Infinium II data is rescaled on the basis of the Infinium I data
assuming a bimodal shape of the methylation density profiles.
However, several researchers have noted that this method is
sensitive to variation in the shape of DNA methylation density
curves and does not work well when the density distribution does
not exhibit well-defined peaks or modes (Pan et al, 2012;
Touleimat and Tost, 2012; Teschendorff et al, 2013).
Three alternative approaches have been proposed recently to
address the limitations of the peak base correction approach. The
first, subset-quantile within-array normalization (Maksimovic et al,
2012), is available in Minfi. Subset-quantile within-array normal-
ization determines an average quantile distribution using a subset
of probes defined to be biologically similar on the basis of CpG
content and allows the Infinium I and II probes to be normalised
together (Maksimovic et al, 2012).
The second, subset quantile normalisation (Touleimat and
Tost, 2012), uses the genomic location of CpGs to create probe
subgroups through which they apply subset quantile normalisation.
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The reference quantiles used in this approach are based on type I
probes with significant detection P-values (Touleimat and Tost,
2012).
Finally, the b-mixture quantile dilation normalisation method,
implemented in the wateRmelon package (Pidsley et al, 2013), uses
quantiles to normalise the type II probe values into a distribution
comparable to the type I probes using a b-mixture model fit to the
type I and type II probes separately and then transforms the
probabilities of class membership of the type II probes into
quantiles (b-values) using the parameters of the b-distributions of
the type I distribution (Teschendorff et al, 2013). This method uses
a three-state b-mixture model but does not use fit to the middle
‘hemimethylated’ component in the normalisation; therefore, it
does not require a trimodal distribution (Teschendorff et al, 2013).
An advantage of BMIQ is that it avoids selecting subsets of probes
matched for biological characteristics as done in the previous
method and was found to be the best algorithm for reducing probe
design bias in a recent paper (Marabita et al, 2013).
Rescaling using the methods mentioned above may be
unnecessary when analysing 450K data on a CpG-by-CpG basis
because the comparisons will be made at the individual probe level.
ADJUSTMENT BATCH/PLATE/CHIP/OTHER
CONFOUNDERS
DNA methylation arrays are susceptible to batch effects: technical
remnants that are not associated with the biological question but
with unrelated factors such as laboratory conditions or experiment
time (Leek et al, 2010; Sun et al, 2011b). Normalisation has been
shown to reduce some component of batch effects, although not all
(Teschendorff et al, 2009; Leek et al, 2010; Sun et al, 2011b). Sound
study design is critical for proper evaluation of and correction for
batch effects: for instance, samples from different study groups
should be split randomly or equally into different batches (Johnson
et al, 2007). By properly correcting for batch effects, one can
combine data from multiple batches, enabling greater statistical
power to measure a specific association of interest (Johnson et al,
2007).
Several methods have been proposed to adjust for batch effects.
ComBat uses an empirical Bayes procedure for this (Johnson et al,
2007), is robust to outliers in small sample sizes and can adjust for
other potential confounders along with batch (Sun et al, 2011b).
However, this method can be computationally burdensome and
was initially developed for gene expression data; therefore, it
requires a transformation of methylation data, which follows the
b-distribution, to satisfy the assumption of normality.
Other R packages exist to adjust for batch effects. MethLAB
(Kilaru et al, 2012) and CpG assoc (Barfield et al, 2012) allow the
adjustment for batch using a mixed-effects model framework.
However, because these methods do not directly adjust the data,
unlike ComBat, they should be used only for a locus-by-locus
analysis.
The array literature indicates that array position effects may also
exist (van Eijk et al, 2012), and thus new batch correction
techniques may be needed to take those into account. When
phenotype distribution is heterogeneous across chips, which can
occur in small samples even after randomisation, methods such as
ComBAT can fail; in this case, linear mixed-effects models treating
chip effects as random is an alternative.
However, in certain cases, the true sources of batch effects or
confounding are unknown or cannot be adequately modelled
statistically (Leek et al, 2010). In such cases, two methods,
surrogate variable analysis (SVA) (Leek and Storey, 2007) and
independent surrogate variable analysis (ISVA) (Teschendorff et al,
2011), also available as the ISVA R package, are very useful.
Surrogate variable analysis estimates the source of batch effects
directly from the array data, and variables estimated with SVA
(SVs) can then be included into the statistical model as covariates
(Leek and Storey, 2007). A modified version of SVA, ISVA,
identifies features correlating with the phenotype of interest in the
presence of potential or unknown confounding factors, which are
modelled as statistically independent surrogate variables or ISVs
(Teschendorff et al, 2011). This method could also be used for
batch effects by constructing ISVs that are associated with these as
potential confounders and including them in the analytical model.
A problem with this technique occurs when the ISVs correlate both
with the phenotype of interest and with the potential confounders,
making model covariate selection difficult. Furthermore, ISVA and
SVA do not directly adjust the methylation data, like ComBAT
does, which may be problematic if the analytical goal is clustering.
One could, however, fit a model with the estimated SVs or ISVs
and compute the residuals for subsequent analyses.
DOWNSTREAM ANALYSIS
Methylation status. Average b or the b-value is a commonly used
metric to denote the level or percentage of methylation for an
interrogated locus. Investigators also use the M-value, or log ratio,
to measure methylation (Du et al, 2010):
M ¼ log2
MaxðM; 0Þ
MaxðU; 0Þ
A normalised M-value near 0 signifies a semimethylated locus, a
positive M-value indicates that more molecules are methylated
than unmethylated, whereas negative M-values have the opposite
interpretation (Du et al, 2010). An M-value is attractive in that it
can been used in many statistical models derived for expression
arrays that assume normality (Du et al, 2010). However, b-values
are much more biologically interpretable than their counterpart;
furthermore, a recent paper found supervised principal compo-
nents analysis (SPCA), as described below, to work better in the
context of b-values as opposed to M-values (Zhuang et al, 2012).
The relationship between the b- and M-value is captured by
(Du et al, 2010):
M ¼ log2
b
1b
Differential methylation/region-based analysis. Locus-by-locus
analyses examine the relationship between a phenotype of interest
and methylation of individual CpG sites across the genome,
seeking to find differentially methylated sites. Differential methyla-
tion analysis aims to determine methylation differences between
the specific groups (such as cases and controls), such as probe-wise
or locus-specific methylation differences; the two terminologies are
therefore equivalent when at the individual locus level. A very
simple example is Delta B (Bibikova et al, 2011; Touleimat and
Tost, 2012), where a difference is applied to two groups’
methylation medians for each CpG locus; if the absolute value of
the difference in medians across samples of each group is higher
than 0.2, then that locus is considered to be differentially
methylated. This 0.2 threshold corresponds to the recommended
difference in methylation between samples that can be detected
with 99% confidence (Bibikova et al, 2011). MethVisual (Zackay
and Steinhoff, 2010) tests whether each CpG site has independent
membership between two groups using Fisher’s exact test; other
packages include (Wettenhall and Smyth, 2004; Barfield et al, 2012;
Kilaru et al, 2012; Wang et al, 2012), some allowing for the
adjustment of potential confounders (Barfield et al, 2012; Kilaru
et al, 2012; Wang et al, 2012). Minfi (Hansen and Aryee, 2013) uses
linear regression and an F-test to test for a univariate association
between the methylation of individual loci and continuous or
BRITISH JOURNAL OF CANCER Processing and analysis of DNA methylation data
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categorical phenotypes, respectively. When sample sizes are o10,
Minfi (Hansen and Aryee, 2013) has options for using limma
(Wettenhall and Smyth, 2004). Specifically, limma uses an
empirical Bayes moderated t-test, computed for each probe, which
is similar to a t-test, except that the standard errors have been
shrunk towards a common value. M-values should be used in these
cases as, being based on a Bayesian Gaussian model, they will rely
much more heavily on the Gaussianity assumption (Zhuang et al,
2012). The IMA package (Wang et al, 2012) allows site
(methylation locus)-specific and region (all loci in a gene)-specific
differential methylation analysis using Student’s t-test and
empirical Bayes statistics. For region analysis, IMA will compute
the mean, median or Tukey’s biweight robust average for the loci
within that region and create an index (Wang et al, 2012).
Methylkit (Akalin et al, 2012) allows for analysis at the site or
regional level using logistic regression or Fisher’s exact test. With
multiple samples per group, methylkit will preferentially use
logistic regression, enabling also the inclusion of potential
confounders (Akalin et al, 2012); to get stable estimates of the
regression coefficients in logistic regression about 10 events per
variable are necessary (Peduzzi et al, 1996).
Differential methylation analysis can also be performed by
measuring variability between methylation loci as opposed to using
statistical tests on the basis of differences in mean methylation
(Xu et al, 2013). This is available in the EVORA package, allowing
an investigator to use differential variability in methylation of
CpGs and to then associate them with a phenotype of interest, such
as cancer status (Teschendorff and Widschwendter, 2012; Xu et al,
2013).
As noted in several recent works, nearby CpG loci tend to have
methylation levels that are highly correlated (Leek et al, 2010). As a
result, statistical analyses that assume independence may be
problematic. Methods are being developed to deal with this
potential problem and include bump-hunting techniques (Leek
and Storey, 2007), which take into account CpG proximity and
borrow strength across neighbouring probes. Although these
approaches were originally developed for CHARM assays, they
may be adapted to the less-dense 450K array, pending careful
attention to the tuning parameters for defining a ‘region’.
Although the above methods have proved successful in
identifying individual CpG sites that associate with some
phenotype/exposure of interest, the extent to which the methyla-
tion of these sites reflect true changes to the methylome or
represent heterogeneity in underlying cell-type distributions
depends largely on the tissue being sampled (Teschendorff et al,
2009; Houseman et al, 2012). We recently developed a set of
statistical methods that exploit the use of leukocyte-specific DMRs
for inferring changes in cell mixture proportions based solely on
peripheral blood profiles of DNA methylation (Houseman et al,
2012). Under certain constraints, this approach can be used to
approximate the underlying distribution of cell proportions among
samples comprising a heterogeneous mixture of cell populations
with distinct DNA methylation profiles (Houseman et al, 2012).
This method has recently been used for predicting cell-type
proportions, which were then subsequently added as additional
covariate terms in a differential methylation analysis of rheumatoid
arthritis cases/controls (Liu et al, 2013). Furthermore, the methods
of Houseman et al (2012) were recently validated using a publicly
available data set (Lam et al, 2012) that consisted of both PBMC-
derived DNA methylation profiles and complete blood cell (CBC)
counts for 94 healthy, non-diseased adult subjects (Koestler et al,
2013).
Clustering/profile analysis. Clustering refers to the grouping of
objects into clusters, such that the objects within the same cluster
are more similar compared with objects in different clusters.
Owing to the interest in identifying molecular subtypes in the
context of cancer, clustering has become a staple technique in the
analysis of array-based DNA methylation data.
Two very well-known non-hierarchical methods used to cluster
DNA methylation include K-means and K-medoids, also known as
partitioning around medoids or PAM (Pollard et al, 2005). Two
disadvantages of K-means are that it requires the prespecification
of the number of classes, which is not often known; furthermore,
K-means create clusters based only on the first moment, which is
problematic in cases where the variance of a specific probe contains
biologically important information. Another commonly used
method to detect patterns in methylation data is PCA, which is a
latent variable method often applied as a dimension reduction
procedure and used for the detection of batch effects (Jolliffe,
2002). Principal component analysis was first applied to genome-
wide Infinium HumanMethylation27 DNA methylation data as
shown in Teschendorff et al (2009). Principal component analysis
is used to develop a smaller number of artificial variables, called
principal components, which account for most of the variance in
the observed variables of a data set (Jolliffe, 2002); usually only the
first few components are kept as potential predictors for statistical
modelling (Jolliffe, 2002). However, additional principal compo-
nents may be of biological significance as shown in Teschendorff
et al (2009). A method to estimate the number of significant PCA
components is available in the ISVA package (Teschendorff et al,
2011). This algorithm is based on the Random Matrix Theory
(Plerou et al, 2002), which can be used to estimate the number of
significant PCA components that are subsequently examined for
their association with study-specific characteristics. Random
Matrix Theory estimates the number of significant components
of a data covariance matrix by comparing the statistics of the
observed eigenvalues obtained from PCA with those obtained from
a random matrix. The main disadvantage with PCA lies in the poor
interpretability of the resulting principal components and the
requirement of a large sample size in order to obtain reliable
results.
Another well-known clustering method is hierarchical cluster-
ing, which builds a binary tree by successively merging similar
samples or probes based on a measure of similarity (Eisen, 1998).
However, because of its unsupervised nature, this form of
clustering may or may not predict a phenotype of interest, as it
does not use data beyond methylation to form clusters. Lumi
(Du, 2008), HumMeth27QCReport (Mancuso et al, 2011) and
methylkit (Akalin et al, 2012) all provide hierarchical clustering
and PCA options using normalised M-values.
In addition to non-parametric techniques for clustering or
profile analysis, Houseman et al (2008) developed a recursive-
partitioning mixture model (RPMM), an unsupervised, model-
based, hierarchical clustering methodology for array-based DNA
methylation data. Recursive-partitioning mixture model assumes a
b-mixture model to split samples between subgroups and provides
an estimate for the number of clusters; furthermore, it is
computationally efficient relative to the standard finite mixture
model approach (Houseman et al, 2008). Owing to the inherent
correlation in the methylation status of nearby CpG sites, there
have also been efforts to incorporate correlation structures based
on the proximity of CpGs in the context RPMM (Leek et al, 2010).
Semisupervised methods use both array-based genomic data
and clinical data for identifying profiles that are associated with a
clinical variable of interest, such as survival. Semisupervised
clustering (SS-Clust) begins by identifying a set of genes that
correlate with a phenotype of interest, followed by unsupervised
clustering of samples based on the set of genes (Bair and
Tibshirani, 2004). Supervised principal components analysis uses
a similar methodology to SS-Clust, but replaces unsupervised
clustering with PCA, providing a ‘risk score’ for each patient,
which is then used as a continuous predictor of survival (Jolliffe,
2002). Semisupervised clustering’s main disadvantage is that it
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requires prespecification of the number of clusters; moreover,
SPCA inherits the interpretability issues characteristic of PCA.
Semisupervised RPMM (Koestler et al, 2010) has been shown to
outperform SS-Clust and SPCA under certain circumstances and
does not require the prespecification of the number of clusters.
One of the first attempts to discover novel tumour classes
through profiling of methylation data involved a supervised
method called support vector machine (SVM) including a cross-
validation method to evaluate its prediction performance (Adorjan
et al, 2002). This approach was initially very computationally
intensive but was a precursor to other profile analysis methods.
Another method, Elastic net, is a shrinkage and selection method,
which produces a sparse model with good prediction accuracy,
while encouraging a grouping effect (Zou and Hastie, 2005); this
algorithm is now being widely used on all types of omics data
(Barretina et al, 2012; Hannum et al, 2013) and was compared with
SVM and SPCA in Zhuang et al, 2012 and shown to be far
superior.
Pathway analysis. Many researchers use pathway analysis to
characterise the function of the gene in which the individual or
group of loci are found. Several software packages do this; however,
we focus on two freely available resources that can also be used in
R. The Gene Ontology (GO) provides a very detailed representa-
tion of functional relationships between biological processes,
molecular function and cellular components across eukaryotic
biology (Ashburner et al, 2000). Another resource that borrows
heavily from GO is PANTHER (Thomas et al, 2003), which relates
protein sequence relationships to functional relationships. How-
ever, many commonly used pathway analysis methods are based on
gene expression correlation or protein–protein interaction;
although pathway perturbations are likely to be evident in
expression changes across all genes of a pathway, a single well-
placed alteration of DNA methylation, acting as an epigenetic
switch, may alter all downstream mRNA expression. In light of
this, sensitivity for detecting significant pathways is lower for DNA
methylation than it might be for mRNA expression. In addition,
unlike mRNA expression, CpGs have different implications for
expression depending on where they exist in relation to a gene or if
they are mapped to any gene at all. As the 450K array has great
heterogeneity with respect to the CpG representation by gene
region, there is the potential for pathway analysis on 450K data to
be biased by CpG selection. In addition, as genes are not equally
covered throughout the array through the number of probes in
their specific regions, this may further bias this analysis. Therefore,
in using such approaches, we recommend stratification by gene
region (e.g., promoter) to decrease the potential for bias. Once a
specific region has been chosen, then pathway analysis, GSEA, or
integration with interaction networks could be a fruitful procedure,
as recently demonstrated in Dedeurwaerder et al (2011b) and West
et al (2013).
MULTIPLE TESTING CORRECTION
Once the analysis has identified top hits, multiple testing correction
is necessary to reduce the likelihood of identifying false-positive
loci by adjusting statistical confidence measures by the number of
tests performed. Bonferroni correction consists of multiplying each
probability by the total number of tests performed; this controls the
family-wise error rate (Holm, 1979).
A less-conservative, widely used, approach involves controlling
the FDR (q-value) or the expected proportion of false discoveries
among the discoveries; this also uses a sequential P-value method
(Benjamini et al, 2001); several R packages allow for the adjustment
of the FDR (Barfield et al, 2012; Kilaru et al, 2012; Wang et al,
2012). All of the aforementioned methods assume statistical
independence of the multiple tests, which can be violated when
tests exhibit strong correlations (as mentioned above); further-
more, q-values imply subsequent validation in an independent
sample, which may not occur. A potential solution to this
independence assumption is with the use of permutation testing
in which the phenotype of interest is randomly re-assigned, and the
data reanalysed. CpG assoc provides a permutation testing option
to obtain empirical P-values (Barfield et al, 2012).
VALIDATION OF SIGNIFICANT HITS
The final step in the proper processing and analysis of DNA
methylation arrays is validation of significant hits by an
independent experimental approach or data resource. The gold
standard is bisulphite sequencing-based methods, such as pyr-
osequencing (Ammerpohl et al, 2009) and Epityper (Laird, 2010),
to provide high-throughput quantitation (Siegmund, 2011).
Another valuable resource for validation (and exploration) of
DNA methylation array data is publicly available repositories such
as the Gene Expression Omnibus (Edgar et al, 2002). Finally, with
the availability of data resources such as the above and HAPMAP
(Altshuler et al, 2010), researchers can now integrate their
methylation array data with these resources, to help further
understand molecular and genomic profiles that contribute to
outcomes of interest such as cancer risk.
CONCLUSIONS
Owing to the plethora and complexity of methods for array
processing and analysis, described above, and to the multitude of
researchers using DNA methylation arrays, there is a need to create
a protocol of good practice to ensure that study results are of the
highest quality possible. Just as gold standard laboratory methods
are crucial to the generation of quality biological data, gold
standard processing and analytical methods are equally as
important. Through the proper use of the processing and analysis
flowchart described above, we hope that potential users will best
harness these powerful array-based tools, which will in turn lead to
rapid discoveries in human health and disease.
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